NCT06439277: An ongoing trial by Eli Lilly and Company
This trial is ongoing. It must report results 2 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06439277 |
|---|---|
| Title | Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 3, 2024 |
| Completion date | Oct. 31, 2027 |
| Required reporting date | Oct. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |